SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the integrated hardware and software infrastructure of the future across space, connectivity, and AI. at core, are builders. The firm design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft. It provides satellite communication services. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is driving intense market conversation following its historic IPO, which saw the company achieve a massive valuation on its first day of trading. Community discourse is sharply divided between retail investors optimistic about the stock's long-term potential for space and AI infrastructure, and skeptics who are highlighting the company's lack of profitability, high valuation relative to earnings, and the influence of heavy institutional buying.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

TRUMP CRYPTO is facing intense volatility as investors debate the legitimacy of the project amid broader market skepticism and comparisons to other political-themed assets. The community remains deeply polarized, with active discussions focusing on potential long-term devaluation, concerns over market manipulation, and the speculative nature of the coin.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares are surging following reports that the streaming company is exploring strategic options, including a potential sale to a U.S. media entity. Investors are actively debating the viability of these buyout rumors and discussing potential acquirers, while also keeping a close eye on the stock's strong technical momentum.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Investors are closely monitoring the latest developments in the Middle East and shifting labor market data, driving heightened volatility across major indices. Community discussion is focused on the potential impact of ongoing geopolitical tensions and upcoming economic releases on market momentum.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a significant pullback, fueled by disappointing May sales data for its flagship drug Yartemlea and fears of potential competition from AstraZeneca. The community is actively debating the reliability of third-party sales data against the company's upcoming J-code reimbursement implementation and regulatory catalysts, while many long-term shareholders are dismissing the volatility as market manipulation and calling for management transparency.

Powerlaw Corp. is a closed-end fund, which engages in investing in artificial intelligence, next-generation software, modern aerospace and defense, and consumer technology platforms. It offers daily liquidity, monthly NAV reporting, quarterly portfolio disclosure, independent governance, and the disclosure standards of a registered investment company. The company was founded on September 9, 2024 and is headquartered in San Francisco, CA.

Powerlaw Corp

Powerlaw Corp is currently under intense scrutiny from the community, with shares experiencing high volatility and significant selling pressure despite the fund's heavy exposure to high-profile private companies like SpaceX and OpenAI. Traders are actively debating whether the recent price decline represents a long-term entry opportunity or a potential pump-and-dump scheme, as they await further updates on the fund's net asset value and the impact of upcoming SpaceX-related market events.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is experiencing high volatility as investors weigh the highly anticipated R2 SUV launch against broader concerns regarding production scaling, profitability, and unfavorable lease pricing. While the community remains deeply divided between bulls citing the long-term potential of the R2 platform and bears focusing on weak execution and cash burn, sentiment is currently pressured by a wider market downturn and skepticism over whether the launch acts as a true turning point.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Carnival Corp shares are trending as investors weigh volatile geopolitical tensions in the Middle East against the company's strong operational metrics and pending corporate restructuring. Community discourse is heavily focused on the stock's sensitivity to oil price fluctuations and potential market manipulation, with many traders actively debating the impact of ongoing peace negotiations and recent virus headlines.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing significant investor attention as it transitions from a legacy film company into a strategic player in domestic pharmaceutical manufacturing and supply chain infrastructure, with community focus centering on anticipated FDA certifications and upcoming earnings. Investors are actively discussing the potential for a massive stock re-rating driven by government onshoring initiatives, tariff impacts on imported drug components, and strategic facility pivots.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors monitor a high-stakes legal dispute with Nippon Shinyaku, with community sentiment largely favoring a resolution that would allow Capricor to gain full commercial control of its Duchenne muscular dystrophy therapy. The discussion centers on the potential for an out-of-court settlement before the upcoming PDUFA date, as the community weighs the impact of the ongoing litigation against the clinical success of its lead candidate and the strategic hire of a new Chief Commercial Officer.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034)  DelveInsight

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast...

Moody Aldrich Partners LLC Reduces Position in Merus N.V. $MRUS

Moody Aldrich Partners LLC reduced its holdings in shares of Merus N.V. (NASDAQ:MRUS - Free Report) by 16.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange...

Insider Buying: Merus (NASDAQ:MRUS) Major Shareholder Purchases 1,052,806 Shares of Stock

Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab purchased 1,052,806 shares of the firm's stock in a transaction on Monday, December 29th. The shares were purchased at an...

A/S Genmab Purchases 1,052,806 Shares of Merus (NASDAQ:MRUS) Stock

Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab bought 1,052,806 shares of the company's stock in a transaction dated Monday, December 29th. The stock was bought at an average...

Insider Buying: Merus (NASDAQ:MRUS) Major Shareholder Acquires 2,978 Shares of Stock

Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab bought 2,978 shares of the company's stock in a transaction that occurred on Friday, December 26th. The shares were acquired at...

Simplify Asset Management Inc. Takes $3.14 Million Position in Merus N.V. $MRUS

Simplify Asset Management Inc. acquired a new position in shares of Merus N.V. (NASDAQ:MRUS - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the...

Merus (NASDAQ:MRUS) Major Shareholder Acquires $9,319,954.00 in Stock

Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab bought 96,082 shares of the firm's stock in a transaction that occurred on Wednesday, December 24th. The shares were purchased...

A/S Genmab Purchases 561,042 Shares of Merus (NASDAQ:MRUS) Stock

Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab purchased 561,042 shares of Merus stock in a transaction on Tuesday, December 23rd. The stock was bought at an average price of...

Insider Buying: Merus (NASDAQ:MRUS) Major Shareholder Acquires 142,610 Shares of Stock

Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab bought 142,610 shares of the stock in a transaction dated Friday, December 26th. The shares were bought at an average cost of...

Merus (NASDAQ:MRUS) Major Shareholder A/S Genmab Acquires 96,082 Shares

Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab purchased 96,082 shares of Merus stock in a transaction that occurred on Wednesday, December 24th. The shares were bought at an...

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.67	--	--	N/A
Q3 '25	-$1.27	--	--	N/A
Q2 '25	-$1.16	-$2.23	-91.48%	MISSED
Q1 '25	-$1.08	-$1.40	-29.73%	MISSED
Q4 '24	-$0.92	--	--	N/A

MRUSMerus N.V

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest MRUS News